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Nerve injuries often lead to neuropathic pain syndrome. The mechanisms contributing to this syndrome involve local inflammatory
responses, activation of glia cells, and changes in the plasticity of neuronal nociceptive pathways. Cannabinoid CB2 receptors contribute
to the local containment of neuropathic pain bymodulating glial activation in response to nerve injury. Thus, neuropathic pain spreads
inmice lacking CB2 receptors beyond the site of nerve injury. To further investigate themechanisms leading to the enhancedmanifesta-
tion of neuropathic pain, we have established expression profiles of spinal cord tissues fromwild-type andCB2-deficientmice after nerve
injury. An enhanced interferon- (IFN-) response was revealed in the absence of CB2 signaling. Immunofluorescence stainings dem-
onstrated an IFN- production by astrocytes and neurons ispilateral to the nerve injury in wild-type animals. In contrast, CB2-deficient
mice showed neuronal and astrocytic IFN- immunoreactivity also in the contralateral region, thusmatching the pattern of nociceptive
hypersensitivity in these animals. Experiments in BV-2microglia cells revealed that transcriptional changes induced by IFN- in two key
elements for neuropathic pain development, iNOS (inducible nitric oxide synthase) and CCR2, aremodulated by CB2 receptor signaling.
The most direct support for a functional involvement of IFN- as a mediator of CB2 signaling was obtained with a double knock-out
mouse strain deficient in CB2 receptors and IFN-. These animals no longer show the enhanced manifestations of neuropathic pain
observed in CB2 knock-outs. These data clearly demonstrate that the CB2 receptor-mediated control of neuropathic pain is IFN-
dependent.
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Introduction
Neuropathic pain refers to pain or increased pain sensitivity
caused by nerve injuries. There is now accumulating evidence
that inflammatory processes at the site of the nerve injury, the
dorsal root ganglia, and the spinal cord projection area contrib-
ute to the complex neuropathic pain pathology. Thus, nerve
damage stimulates peripheral immune cells including neutrophil
granulocytes, macrophages, mast cells, and T-lymphocytes fol-
lowed by the activation of spinal cord microglia and astrocytes
(Scholz andWoolf, 2007). The immune response is orchestrated
by inflammatory mediators including cytokines, chemokines,
ATP, neuropeptides, prostaglandins, and endocannabinoids
(DeLeo andYezierski, 2001; Clark et al., 2007). Endocannabinoid
signaling through CB2 receptors (Zhang et al., 2003) attenuates
microglial activation and controls the regional restriction of the
neuropathic pain (Ehrhart et al., 2005; Romero-Sandoval and
Eisenach, 2007). On sciatic nerve ligation, mice lacking CB2 re-
ceptors show an enhanced microglia response (Racz et al., 2008).
Thus, activated microglia are found not only in the spinal cord
region ipsilateral to the peripheral nerve injury as observed in
wild-type controls, but rather throughout the spinal cord. The
enhanced microglia response is accompanied by a more wide-
spread neuropathic pain response with enhanced pain sensitivity
in the ipsilateral and contralateral sites. Conversely, overexpres-
sion of CB2 receptors in neurons and microglia resulted in a
significant reduction of neuropathic pain responses. To further
elucidate the cellular and molecular mechanism involved in the
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enhanced neuropathic pain response in the absence of CB2 recep-
tor signaling, we have now established expression profiles from
the affected spinal cord tissues. Our analysis provides strong ev-
idence for an involvement of interferon- (IFN-) as a mediator
of CB2 signaling in neuropathic pain.
Materials andMethods
Animal experimental conditions. Animals were housed in groups of three
to five and had ad libitum access to water and food. The housing condi-
tions were maintained at 21 1°C and 55 10% relative humidity in a
controlled light/dark cycle (light on between 8:00 A.M. and 8:00 P.M.).
All experimental procedures and animal husbandry were conducted ac-
cording to standard ethical guidelines (European Community Guide-
lines on the Care and Use of Laboratory Animals 86/609/EEC) and ap-
proved by the local ethical committee (Comite´ Etico Experimental
Animal–InstitutoMunicipal de Asistencia Sanitaria/Universitat Pompeu
Fabra, Bezirksregierung Ko¨ln). All experiments were performed under
blind conditions.
Behavioral experiments. Hyperalgesia to noxious thermal stimulus
(plantar test) and allodynia to mechanical stimuli (von Frey stimulation
model) were used as outcomemeasures of neuropathic pain. In the plan-
tar test, the mean paw withdrawal latencies for the ipsilateral and con-
tralateral hindpaws were determined from the average of three separate
trials, taken at 5 min intervals to prevent thermal sensitization and be-
havioral disturbances using a commercially available apparatus (Ugo
Basile Biological Research Apparatus) (Hargreaves et al., 1988). The von
Frey filament stimulation experiments were conducted with a Dynamic
Aesthesiometer (Ugo Basile Biological Research Apparatus). Clear paw
withdrawal, shaking, or licking was considered to be a nociceptive-like
response (Chaplan et al., 1994).
IFN-/ (eight males for nerve injury plus six males for sham) and
double IFN-//CB2
/ (sevenmales for nerve injury plus threemales
for sham) animals were used. Mice were first habituated for 1 h to each
different experimental test once daily during 4 d. After the habituation
period, baseline responses were established during 2 consecutive days for
each paradigm in the following sequence: von Frey model and plantar
test (30 min later). All the behavioral tests were performed in the same
group of animals. One day after baseline measurements, sciatic nerve
injurywas induced. A partial ligation of the sciatic nerve atmidthigh level
just proximal to the trifurcation was performed with one thigh ligature
using a 9-0 silk thread to induce neuropathic pain, as previously de-
scribed (Malmberg and Basbaum, 1998). IFN-/ and IFN-//
CB2
/ mice were tested in each paradigm on days 3, 6, 8, 10, and 15
after the surgical procedure using the same sequence as used for baseline
responses. Data were compared each experi-
mental day by using a two-way ANOVA (sur-
gery and genotype as between-group factors)
followed by corresponding one-way ANOVA
when appropriate.
Microarray experiments. Male and female
CB2 knock-out (CB2
/) mice and wild-type
littermates (CB2
/) on a C57BL/6J congenic
background (Buckley et al., 2000) were used. At
the end of the behavioral experiments (Racz et
al., 2008), the mice were killed and the lumbar
section of the spinal cords was rapidly dissected
and fresh-frozen in liquid nitrogen. Tissue was
stored at80°C until RNA isolation. The sam-
ples were analyzed by MG_430 2.0 Affymetrix
GeneChips in single array. Total RNA was ex-
tracted from spinal cord after mechanical ho-
mogenization using TRIzol (Invitrogen).
mRNA was purified using RNeasy Mini kit
(QIAGEN) according to themanufacturer’s in-
structions. The tissue samples from nine ani-
mals were pooled. Samples yielded 20 g of
total RNA. RNA integrity was assessed using
Agilent Bioanalyzer 2100 (Agilent). Five micro-
grams of total RNA was converted into double-
stranded cDNA using T7-oligodT coupled primers per manufacturer’s
instructions. Ten micrograms of all fragmented cDNA samples were hy-
bridized to MG_430 2.0 Affymetrix GeneChips following the manufac-
turer’s instructions. All samples reported a glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and-actin average 3-to-5 ratio0.9 on the
GeneChips, respectively. All mice reported a comparable number of
genes expressed (58.1% in treated and 57.4% in the control groups).
Microarray expression values were generated using MAS5 software
“ArrayAssist 3.0” (Stratagene). The MAS5-obtained log2-transformed
expression values were compared between tissues from sham-operated
and sciatic nerve-ligated animals. A total of 490 transcripts were found to
be differentially regulated by the nerve ligation at a level of p 0.05. We
further eliminated all transcripts that were upregulated or downregu-
lated by more than twofold in two or more sham-operated tissues, and,
furthermore, all those transcripts with absolute expression values 20.
This selection yielded 219 transcripts for additional analysis.
Bioinformatics analysis of the promoter regions of the differentially regu-
lated genes reported in the microarray study. Promoter regions spanning
from600 to100 bp relative to the transcription start site were down-
loaded from public domain at University of California Santa Cruz
(mouse genome assembly mm9). Duplicated RefSeq identifiers and
overlapped regions were discarded to generate a nonredundant sequence
dataset. Matches to putative regulatory motifs were obtained with 126
JASPAR transcription factor matrices at 0.90 similarity threshold (Sand-
elin et al., 2004). Motif overrepresentation was evaluated using 10,000
randomly sampled datasets of the same size taken from the rest of pro-
moter sequences. Empirical p value as (r  1)/(n  1) were estimated
fromoccurrences distribution for each specificmatrix on randomly sam-
pled datasets. In addition, random expectation (RE) was calculated from
100 datasets of 18,983 synthetic promoters. Each synthetic promoter
sequence was generated using order-1 Markov chains from GpC, GC-
rich or AT-rich regions obtained on nonredundant and nonoverlapping
real promoters (Bellora et al., 2007). RE provides information on the
noise of the motif prediction (a high number of hits usually indicates
poor matrix quality) and on relative enrichment (observed/expected). A
value of p 0.01 was considered to be significant for all the analyses and
motifs with enrichments2 were excluded.
Validation procedure. Igtp, Tgtp, and Gbp2 mRNA were quantified by
RT-PCR using gene expression assays (Applied Biosystems: Igtp,
Mm00497611_m1; Tgtp, Mm00786926_s1; Gbp2, Mm00494575_m1).
The real-time PCR amplifications were performed with the Taqman
7900HT from Applied Biosystems in 20 l reaction volumes. Thermal
cycling proceeded with one amplification cycle of denaturation at 95°C
for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.
Figure 1. Classification of genes showing significant changes in expression in the spinal cord after sciatic nerve injury. About
one-third of upregulated genes are responsible for the inflammatory/immunological processes, whereas only a small amount of
genes belonging to this category was downregulated. A large number of genes involved in signaling and metabolism were
upregulated and downregulated. A fewer number of genes regulating cell structure, translation/transcription, and DNA repair
functions are in rather equal number upregulated or downregulated. A large number of genes with unknown function have a
different expression after sciatic nerve injury.
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Results were expressed as the relative amount of Igtp, Tgtp, and Gbp2
normalized by -actin expression. All reactions were performed in trip-
licate, and the data were analyzed with SDS analyzing software (Applied
Biosystems; SDS 2.2.2) as described previously (Livak and Schmittgen,
2001).
Double immunofluorescence staining. Five mice per group were anes-
thetized with ketamine/xylacin (50/10 mg/kg) and then intracardially
perfusedwith heparinized phosphate buffer, followed by 4%paraformal-
dehyde. The lumbar region of the spinal cord was removed and cryopre-
served in 30% sucrose solution at 4°C. The section from L2 to L6–S1 of
the spinal cord was selected and then embedded in OCT, sliced in 25m
sections on a cryostat, and six sections per mice and two mice per slide
mounted in Star frost-coated slides.
The slides were incubated in anti iba-1 antibody (1:200; Wako Chem-
icals) formicroglia staining or polyclonal GFAP antibody (1:1000; Dako)
for astrocyte staining and monoclonal anti-IFN- antibody (1:150; Mil-
Figure 2. Affymetrix gene array analysis of spinal cord tissues during neuropathic pain development in CB2
/mice. A, The list of genes that weremore strongly regulated in CB2
/ animals
comparedwith CB2
/mice.B, Genes thatweremore strongly regulated in CB2
/ animals comparedwith CB2
/mice. The intensity anddirection of gene regulation are represented in aheat
map (red, downregulated; green, upregulated).
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lipore Bioscience Research Reagents) at the same time at 4°C overnight.
The double immunofluorescence staining was followed by incubation
with CY3-conjugated anti-rabbit secondary antibody (1:500; Jackson
ImmunoResearch) for iba-1 or GFAP, and biotinylated anti-rat second-
ary antibody (1:500; Vector) for IFN- for 1 h. After one wash with
phosphate buffer (0.1 M), the slides were incubated with streptavidin
Alexa Fluor 488 (1:500; Invitrogen).
For the low-magnification images, the stained sections of the lumbar
dorsal horn were viewed at 10 objective and recorded with a Leica
DMR microscope equipped with digital camera Leica DFC 300 FX.
Confocal images were obtained using a Leica SP2 confocal micro-
scope, adapted to an inverted Leica DM IRBE microscope. Tissue
sections of the lumbar dorsal horn were examined with a 40, 1.25
numerical aperture oil-immersion in Leica Plan Apochromatic objec-
tive at zoom of 2. Alexa Fluor 488 and CY3 were excited with the 488
nm line of an argon laser and the 543 nm line of a green neon laser,
respectively, and double immunofluorescence images of three stained
sections were taken for each animal in a sequential mode. From each
section were always recorded images of the ipsilateral and contralat-
eral dorsal horns. Fifteen images were analyzed for each experimental
groupwith Image J softwareandanalyzed for thecolocalizationofGFAPand
IFN- with the intensity correlation analysis plugin (Li et al., 2004). Data
were compared by using one-way ANOVA and least significant difference
post hoc analysis.
Results
Transcriptional changes induced by peripheral nerve injury
To evaluate transcriptional events at the level of the spinal cord
that may underlie the increased pain sensitivity after nerve injury
and the enhanced neuropathic pain phenotype of CB2
/ ani-
mals, we performed a series of microarray experiments in
CB2
/ and CB2
/mice. For this purpose, we dissected lumbar
spinal cord segments ipsilateral and contralateral to the nerve
ligation from CB2
/ and CB2
/mice, plus the corresponding
sham controls. RNA from these tissues was isolated and analyzed
on Affymetrix GeneChip arrays (MG_430 2.0).
We found 490 genes differentially expressed in tissues from
animals with nerve injury compared with sham control. Of these
transcripts, we excluded from additional analysis all those with
expression levels 0.5% of -actin and those showing differen-
tial expression (more than log 1) in more than one of the sham
control tissues. We thus obtained a total of 219 transcripts, of
which 117 were downregulated and 102 upregulated (supple-
mental Table S1, available at www.jneurosci.org as supplemental
material). These transcripts included a large number of genes
with a function in cell signaling, regulation of gene expression
Figure 3. Expression of genes regulated by IFN- or IFN- after partial sciatic nerve ligation (PNL) was upregulated. A, The increase in expression level of IFN--regulated genes was more
intensive in CB2
/ than in CB2
/mice, whereas the upregulation in IFN--regulated geneswas less intensive in CB2
/ animals.B, Taqman real-time PCR analysis of the expression of three
GTPase regulated genes also showed a stronger expression change in CB2
/ than in CB2
/mice after neuropathy. wt-i, Ipsilateral paw of CB2
/mice; wt-c, contralateral paw of CB2
/
mice; ko-i, ipsilateral paw of CB2
/mice; ko-c, contralateral paw of CB2
/mice.
Table 1. Identification of regulatory motifs in genes upregulated after nerve injury
TFBS  
matrix 
name 
TFBS
matrix  
logo
Observed 
sites on 
target 
dataset 
Expected sites 
on synthetic 
sequence 
datasets 
(enrichment)
Expected sites 
on random 
promoter 
datasets 
(enrichment) 
Genes
 with 
 sites 
Over- 
representation
obs./exp. sites 
epval. 
IRF1 20 1.73 (11.53x) 3.38 ( 5.92x) 16 (22.2%) 1.0e-4 
IRF2 6 0.05 (122.84x) 0.10 (61.66x) 5 ( 6.9%) 1.0e-4 
Transcription factor binding site (TFBS)matrix name indicates the identifier from a JASPAR positionweightmatrices (PWM) collection. The TFBSmatrix logo represents the transcription factor binding site sequences, inwhich the size of the
letter is ameasure of nucleotide frequency. Logos of TFBS can be read in forward or reverse, so the complementary logo is also valid for any PWM. The observed sites on the target dataset identify the total number of sites detected. Compared
with the expected sites on synthetic sequence datasets or random promotor datasets, IRF-1 and IRF-2 binding sites were enriched in our dataset (number in brackets). Genes with sites represent the number of genes with at least one site.
Overrepresentation obs./esp. sites, epval.: epval, empirical p value indicating the probability of obtaining at least the same number of sites on random datasets as the one observed.
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and immune responses (Fig. 1), which is consistent with the ob-
served microglia response triggered by the nerve injury (Racz et
al., 2008). Most of the suppressed, 93, and one-half, 47, of the
induced transcripts were more strongly regulated on the ipsilat-
eral compared with the contralateral side (supplemental Table 1,
available at www.jneurosci.org as supplemental material).
We considered those transcripts that were more strongly in-
duced or repressed in CB2
/ animals, or vice versa, as potential
candidate mediators of the enhanced neuropathic pain pheno-
type. Indeed, 54 transcripts were more strongly regulated in
CB2
/mice and 36 in CB2
/mice (Fig. 2).
Enhanced upregulation of interferon--inducible transcripts
in CB2 knock-out mice
We next performed a bioinformatics analysis to obtain the can-
didate cis-regulatory motifs and their binding transcription fac-
tors in a given dataset of coregulated genes. This method was
specifically developed to identify regulatorymotifs that are highly
specific for a group of genes under study (N. Bellora andM. Alba`,
unpublished data). In this analysis, we used 72 promoter regions
of the genes differentially regulated after nerve injury in both
genotypes, as revealed bymicroarray experiments (supplemental
Table 1, available at www.jneurosci.org as supplemental mate-
rial). We identified a significant overrepresentation of transcrip-
tion factor interferon regulatory factor-1 (IRF-1) and IRF-2
binding sites ( p 0.001) in 22.2 and 6.9% of the genes analyzed,
respectively, thus indicating a high enrichment over synthetic
sequences and random promoter datasets (Table 1).
These data indicate a strong interferon response after nerve
injury. Interestingly, a number of IFN--induced genes were
among those transcripts that were more strongly regulated in the
absence of CB2 receptors (Fig. 3A). These transcripts included
severalmembers of the 47 kDa and 65 kDa families ofGTPases. In
CB2
/ animals, we observed a 1.7- to 2.4-fold upregulation,
with the exception of Tgtp, which was 3.6 times higher, whereas
these transcripts were 2.3- to 7-fold upregulated in CB2
/mice.
Validation of three of these genes using Taqman real-time PCR
analysis confirmed their stronger induction in CB2
/ animals
(Fig. 3B). IFN-inducible GTPases such as Igtp and Gbp2 have
been implicated in the regulation of immune responses toward
infections (Martens and Howard, 2006; Degrandi et al., 2007).
These results suggest an enhanced IFN- response in CB2
/
mice after nerve injury.
The enhancedmanifestations of neuropathic pain were not
observed in double IFN-//CB2
/mice
To clarify the involvement of interferon proteins in the enhanced
manifestations of neuropathic pain in CB2
/ mice, we crossed
CB2
/ animals to IFN-/mice to generate double knock-out
mice deficient in both CB2 receptors and IFN-. These double
knock-out animals showed no gross behavioral phenotypes or
any obvious symptoms of a disease.
We therefore subjected these mice to a peripheral nerve liga-
tion and evaluated hyperalgesia to a noxious thermal stimulus
(plantar test), and allodynia to a mechanical stimulus (von Frey
stimulation model) as outcome behavioral measures of neuro-
pathic pain at various time points after the nerve injury. Baseline
nociceptive responses of IFN-/ and double IFN-//
CB2
/mice were similar in the plantar test and von Frey stim-
ulation model. Sham operation also did not produce any modi-
fication of these nociceptive thresholds in both genotypes.
Furthermore, thermal hyperalgesia and mechanical allodynia in-
duced by sciatic nerve injury in the ipsilateral pawwere similar in
IFN-/ and double IFN-//CB2
/ mice (Fig. 4) and no
mirror image of pain was revealed in any experimental group.
Thus, the enhanced manifestations of neuropathic pain in
CB2
/micewas completely suppressed in the absence of IFN-.
Therefore, IFN- is directly involved in the regulation of neuro-
pathic pain responses by CB2 receptors.
Immunofluorescence analysis of IFN- expression in
microglial cells and astrocytes
To further study IFN- in activated microglia and astrocytes un-
der these experimental conditions, double immunofluorescence
analysis was performed using antibodies against iba-1 or GFAP
and IFN- in CB2
/ and wild typemice exposed to sciatic nerve
injury. IFN- signals were detected in the dorsal horn of lumbar
spinal cord mainly in the ipsilateral side of CB2
/mice, as well
as in the ipsilateral and contralateral sides of CB2
/mice. IFN-
immunoreactivity could be detected in aminor subset of GFAP
astrocytes but did not colocalize with ibamicroglial cells. Using
the intensity correlation analysis, we observe that the colocaliza-
tion of IFN- signal with the GFAP signal was significantly en-
hanced in the ipsilateral and contralateral dorsal horns of the
CB2
/mice, whereas in CB/ this effect was only revealed in
the ipsilateral dorsal horn. The expression of IFN- in astrocytes
matched the pattern of nociceptive hypersensitivity (see Fig. 6).
IFN- protein has also been reported to be expressed in neurons
(Neumann et al., 1997). Indeed, a positive IFN- staining was
observed in the cytoplasm of cells recognized as neurons by their
morphology (Fig. 5) identifying spinal cord neurons as a poten-
tial source for IFN- after nerve injury.
Figure 4. Development of neuropathic pain in male IFN-/ and IFN-//CB2
/
knock-out animals. A single tight ligature around one-third or one-half of sciatic nerve was
made to induce the neuropathic pain. Mice were tested in the ipsilateral and contralateral paw
for evaluatingmechanical allodynia (vonFreymodel) and thermalhyperalgesia (plantarmodel)
on days 3, 6, 8, 10, and 15 after surgery. Mechanical allodynia data are expressed as mean
SEM percentage values of basal responses of sham-operated mice. Thermal hyperalgesia data
are expressed as mean SEM values of withdrawal latencies. The black stars represent com-
parisons between time points in IFN-/ animals (n	 8 for nerve injury, n	 6 for sham).
The white stars represent comparison between time points in IFN-//CB2
/mice (n	
7 for nerve injury; n	 3 for sham). One star, p 0.05; two stars, p 0.01; three stars, p
0.001.
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Role of the CB2 receptor in IFN--inducible inducible nitric
oxide synthase mRNA and CCR2mRNA expression in
microglial cells
Peripheral nerve injury induced inflammation is associated with
enhanced gene transcription of inducible nitric oxide synthase
(iNOS) and nitric oxide (NO) release from locally recruitedmac-
rophages andmicroglial cells (Martucci et al., 2008). Recent stud-
ies demonstrated that spinal microglial infiltration in neuro-
pathic pain is critically dependent on binding of chemokine
monocyte chemoattractant protein-1 [MCP-1; chemokine li-
gand 2 (CCL2)] to its receptor CCR2 expressed on infiltrated
microglial cells (Zhang et al., 2007). To test
the hypothesis that IFN--inducible iNOS
andCCR2 gene expression is influenced by
CB2 signaling in microglial cells, we stim-
ulated BV-2 microglial cells with IFN- in
the presence or absence of the CB2 agonist
(6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,
10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo
[b,d]pyran (JWH-133) (Fig. 7).mRNAex-
pression of CB2 is upregulated in IFN-
stimulated BV-2 cells and unaffected by
treatment with JWH-133 and the CB2-
selective antagonist N-[(1S)-endo-1,3,3-
trimethylbicyclo[2.2.1]heptan-2-yl]-5-(4-
chloro-3-methylphenyl)-1-(4-methylbenzyl)-
pyrazole-3-carboxamide (SR144528) (SR2).
However, exposure of IFN--stimulated
microglial cells to JWH-133 inhibited
iNOS gene expression, whereas the CB2
antagonist SR144528 was able to reverse
this effect (Fig. 7). This demonstrates that
this inhibitory effect of the JWH-133 is in-
deedmediated by the CB2 receptors. Next,
we tested the influence of CB2 receptor sig-
naling on CCR2 mRNA expression in
BV-2 microglial cells after stimulation
with IFN-. Treatment of BV-2 cells with
JWH-133 significantly diminishes IFN-
dependent CCR2 mRNA upregulation in
BV-2 cells. This inhibitory effect was fully
reversed in the presence of the CB2 antag-
onist SR144528. These findings suggest
that CB2 signaling significantly downregu-
lates IFN--dependent iNOS and CCR2
gene expression in microglial cells, the
gene products of which are critically in-
volved in activation and chemotaxis ofmi-
croglial cells after peripheral nerve injury.
Discussion
The present results revealed the crucial
role of CB2 cannabinoid receptors in the
development of neuropathic pain through
an immune mechanism linked to modi-
fied IFN- activity. Hyperalgesia and allo-
dynia induced by sciatic nerve injury were
enhanced in CB2
/mice, as revealed by a
mirror image of pain in the contralateral
side. These behavioral manifestations of
neuropathic pain matched the changes in-
duced in microglial and astrocyte activa-
tion, astrocytic IFN- expression, and
other biochemical parameters related to
the immune response.
Glial activators include chemokines that enhance pain sensa-
tion and are under the control of immune mediators, as well as
several neuromodulators released by nearby neurons, such as
prostaglandins (Tanga et al., 2006). Interferons represent crucial
modulators of the central and peripheral immune responses
(Bach et al., 1997) and the enhanced induction of IFN- genes in
CB2
/ mice could participate in their nociceptive hypersensi-
tivity. Indeed, a prolonged spinal increase in IFN- levels in in-
flammatory responses in diseases such as viral infections and
Figure 5. IFN- expression by astrocytes and neuronal cells in the spinal cord of CB2
/ and CB2
/mice after sciatic nerve
injury. A, Representative low-magnification images of double immunofluorescence staining with GFAP (astrocyte: red, CY3-
conjugated secondary anti-rabbit Ab) and IFN- (green, streptavidin Alexa Fluor 488) recordedwith 10 objective in the lumbar
dorsal horn of sciatic nerve injury CB2
/ and CB2
/mice.B, Confocal microscopy of representative spinal cord sections after
double immunofluorescence staining for microglial marker iba-1 or astrocyte marker GFAP (red, CY3-conjugated secondary anti
rabbitAb) and for IFN- (green, streptavidinAlexaFluor 488). IFN-expression inGFAPastrocytes andnot iba-1microglial cells
in the lumbar dorsal horn of CB2
/ and CB2
/mice. C, IFN- immunoreactivity in neuron-like cells as evidenced by neuronal
morphology in the ventral horn of spinal cords of neuropathic WT mice. IFN- expression was visualized by staining of cryostat
sections with rat anti-IFN- antibody and a biotinylated anti-rat secondary antibody followed by streptavidin Alexa Fluor 488
(green). D, Colocalization of GFAP with IFN- in the ipsilateral dorsal horn of neuropathic CB2
/mice. GFAP was visualized by
staining of cryostat sections with rabbit anti-GFAP antibody followed by CY3-conjugated secondary anti-rabbit antibody (red).
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multiple sclerosis, is thought to contribute
to the associated persistent pain states
(Miyazaki et al., 2008). Furthermore,
IFN- treatments in cancer therapy can re-
sult in spontaneous pain in humans (Que-
sada et al., 1986; Mahmoud et al., 1992).
Intrathecal IFN- administration in mice
can also cause pain-related behaviors in
normal, but not in IFN- receptor knock-
out mice (Robertson et al., 1997). Al-
though the molecular and cellular mecha-
nism of interferon-induced pain remains
mostly unclear, it has been demonstrated
that IFN- can cause spontaneous firing of
dorsal horn neurons in vitro and in vivo, as
well as enhanced wind-up responses to
electrical stimulation (Vikman et al., 2003,
2005, 2007). Interestingly, the pharmaco-
logical activation of CB2 cannabinoid re-
ceptors suppresses wind-up responses of
spinal nociceptive neurons and this effect
was more pronounced in the presence of
pathological pain (Nackley et al., 2004).
The enhanced IFN- response revealed
by microarray experiments in CB2
/
mice exposed to nerve injury has an im-
portant functional relevance in vivo. Thus,
a direct relationship between the enhanced
IFN- response and the neuropathic pain
manifestations of CB2
/ mice was dem-
onstrated by using double knock-out ani-
mals deficient in CB2 receptors and IFN-.
The behavioral phenotype of CB2
/mice
showing an enhanced neuropathic pain
was completely abolished in these double
knock-out animals. IFN- is a crucial
modulator of the central and peripheral
immune responses suggesting that an im-
mune alteration seems to underline the
neuropathic pain responses in CB2
/
mice.
The manifestations of neuropathic
pain observed in CB2
/mice and double
knock-out mice deficient in CB2 and
IFN- suggest that endocannabinoids play
an important role in the control of the im-
mune responses leading to the develop-
ment of neuropathic pain. In support of
this hypothesis, an enhancement in the
levels of the two main endocannabinoids,
anandamide and 2-arachidonoyl-glycerol,
was revealed after sciatic nerve injury in
the spinal cord and several brain areas in-
volved in pain, such as the periaqueductal
graymatter and the rostral ventralmedulla
(Petrosino et al., 2007). The endocannabi-
noid levels were also enhanced after sciatic
nerve injury in the dorsal root ganglia (Mitrirattanakul et al.,
2006) and the section of the sciatic nerve proximal to the lesion
(Agarwal et al., 2007). These increased endocannabinoid levels
are likely related to enhanced biosynthesis or decreased catabo-
lism and transport because endocannabinoids are produced on
demand without any substantial storage (Di Marzo, 1998).
Therefore, endocannabinoids could produce a tonic activation of
CB2 receptors after sciatic nerve injury that would limit the im-
mune responses leading to the development of neuropathic pain.
In agreement, both mechanical and thermal hyperalgesia pro-
duced after sciatic nerve injury were attenuated by the adminis-
tration of N-arachidonoyl-serotonin, an inhibitor of fatty acid
Figure 6. Intensity correlation analysis for the colocalization of GFAP with IFN- in CB2
/ and CB2
/mice after sciatic
nerve injury. A, Representative intensity correlation plots of GFAP (astrocyte) (red channel) and IFN- (green channel) in the
ipsilateral dorsal horn of a CB2
/ mice after nerve injury. GFAP was visualized by staining of cryostat sections with rabbit
anti-GFAP antibody followed by CY3-conjugated secondary anti-rabbit antibody (red). IFN- expression was visualized by stain-
ingof cryostat sectionswith rat anti-IFN-antibodyandabiotinylatedanti-rat secondary antibody followedby streptavidinAlexa
Fluor 488 (green). B, Scatter plot of pixel staining intensities of the same image. C, Image of the product of the differences of the
mean values (PDM)of the same image.D, Intensity correlation quotients for the different experimental groups (n	5). Thewhite
bars represent the contralateral dorsal horn, and the black bars represent the ipsilateral dorsal horn. Error bars indicate SEM. The
black stars represent comparisons between sham-operated and nerve injury, or between ipsilateral and contralateral paw. The
white stars represent comparisons between genotypes. Two stars, p 0.01; three stars, p 0.001.
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amide hydrolase, the enzyme responsible for the degradation of
anandamide (Maione et al., 2007), which further support the role
of endocannabinoids in the modulation of neuropathic pain.
In contrast with the results here obtained in CB2
/mice, the
genetic disruption of the CB1 receptor had no major conse-
quences on the development of neuropathic pain (Castan˜e´ et al.,
2006) despite the high expression of these receptors in the CNS
(Tsou et al., 1998). However, CB1 receptors expressed in periph-
eral nociceptors but not in the CNS seem to be involved in the
manifestations of neuropathic pain (Agarwal et al., 2007). In
agreement, pharmacological activation of CB1 receptors have
also been reported to reduce pain sensitivity in a variety of neu-
ropathic pain models (Pertwee, 2005).
Subsequent to nerve injury, gradients formed by CCL2 and
CCL3 orchestrate the recruitment and activation of resident and
monocyte-derived microglia via signaling through their respec-
tive receptorsCCR2,CCR1, andCCR5 (Scholz andWoolf, 2007).
In particular, CCR2 expression in either resident microglia or
bone marrow-derived macrophages may be sufficient for the de-
velopment ofmechanical allodynia in amurine neuropathic pain
model (Zhang et al., 2007). CB2 cannabinoid receptor activity
may critically influence the induction of CCR2 expression by
monocytes and thus inhibit their chemotaxis (Steffens et al.,
2005). Moreover, endocannabinoids were found to abolish mi-
croglia activation by inhibiting NO release through amechanism
linked to theMAPK (mitogen-activated protein kinase) pathway
(Eljaschewitsch et al., 2006). Our data revealed that IFN- treat-
ment of mouse BV-2 microglial cells evoked marked microglial
activation as indicated by induction of iNOS and CCR2 gene
expression. CB2 signaling, however, interfered with the expres-
sion of these two IFN--inducible genes in BV-2 cells. These data
suggest that CB2 receptor signaling exerts antiinflammatory ef-
fects in the neuropathic response by controlling IFN--mediated
microglial activation and recruitment. Therefore, these data
complement our in vivo observations in the neuropathic re-
sponse in CB2
/mice.
Mice genetically modified either by increasing or eliminating
specific gene may be limited by the fact that this genetic change
may be affecting not only the target gene but also other biological
components, perhaps participating in the effects evaluated in
these genetic models. Therefore, pharmacological studies using
selective ligands of CB2 receptors would be useful to confirm the
relevance of the present results. Nevertheless, these genetic ma-
nipulations have been considered a key approach to the identifi-
cation of alterations associated to different pathological condi-
tions and to the discovering of new potential therapeutic targets
in a variety of neuropsychiatric disorders. In this study, the ac-
cording results obtained in CB2
/mice and double knock-out
mice deficient in CB2 and IFN- together with the pharmacolog-
ical studies performed in vitro further support the relevance of the
findings.
Our immunofluorescence analysis revealed that IFN- was
mainly expressed in neurons after sciatic nerve injury and this
expression of IFN- matched the pattern of nociceptive hyper-
sensitivity in all experiments. IFN- expression was also present
in astrocytes, but absent in microglia. Previous studies have re-
ported the presence of CB2 receptors inmicroglial cells (Romero-
Sandoval et al., 2008) and neurons (Van Sickle et al., 2005). How-
ever, the possible presence of CB2 receptors in neurons and its
possible functional role is still a controversial issue that requires
additional investigation. Taken all these data into consideration,
we can postulate a mechanism to explain the modulation of neu-
ropathic pain through CB2 receptor activation (Fig. 8). Thus, the
neuroinflammatory process leading to the development of neu-
ropathic pain seems to be initiated by the microglial activation
produced after nerve injury (Scholz and Woolf, 2007). This pro-
cess requires a coactivation of astrocytes, which, together with
neurons, release IFN- and promote consolidation and progres-
sion of the neuropathic pain state (Zhang et al., 2007). IFN-
promotesmicroglia activation by the induction of several inflam-
matory pathways, including an enhancement in iNOS and CCR2
activity. Interestingly, previous studies have reported the expres-
sion of IFN- receptors in microglial cells and its modulation
under pathological conditions (Cannella and Raine, 2004). CB2
receptors on microglial cells would play a crucial role to control
and limit the spreading of this neuroinflammatory process. Thus,
the activity of CB2 receptors in microglial cells would reduce the
activation of these cells during neuropathic pain by regulating the
expression of iNOS and CCR2. In the absence of CB2 receptors,
IFN-would produce amorewidespread activation ofmicroglial
cells, which would enhance the manifestations of neuropathic
pain and would be responsible for the presence of amirror image
of pain in the contralateral side.
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